Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736 | 0.82 | TRPV1 (0.66) | LMNATYRTRPV1TSHRMGLL | |
| SCHEMBL16547260 | 0.81 | MGLL (0.52) | TRPV1TSHRMGLL | |
| SCHEMBL24996834 | 0.81 | CA2 (0.45) | TSHRORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL22193399 | 0.79 | TSHR (0.50) | LMNATYRTRPV1TSHRHDAC1 | |
| SCHEMBL14477120 | 0.78 | TRPV6 (0.67) | TSHRALDH1A1ORAI1ORAI2ORAI3 | |
| SCHEMBL5510327 | 0.76 | TRPV1 (0.59) | LMNATYRTRPV1TSHRMGLL | |
| SCHEMBL257878 | 0.76 | TRPV1 (0.59) | LMNATYRTRPV1TSHRMGLL | |
| SCHEMBL28120485 | 0.76 | TRPV1 (0.59) | LMNATYRTRPV1TSHRMGLL | |
| SCHEMBL16491634 | 0.76 | TSHR (0.52) | LMNATYRTRPV1TSHRHDAC1 | |
| SCHEMBL22960550 | 0.75 | TRPV1 (0.44) | LMNATYRTRPV1TSHRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2014-06-12 | — | — | US | disclosed |
| US-8304579-B2 | Boronic acid aryl analogs | JOHNS HOPKINS UNIVERSITY (US) | 2012-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | LMNA 1148/4885TYR 4876/4885TRPV1 3537/4885 |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | TNFSF11, CD14, TNFRSF1A | LMNA 537/4885TYR 4809/4885TRPV1 140/4885 |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | LMNA 1549/4885TYR 4854/4885TRPV1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.